Last checked at 
(Alliance News) - Oxford BioDynamics PLC on Friday said it has entered into a master service agreement for the development of predictive EpiSwitch biomarkers with an undisclosed US pharmaceutical company.
This agreement builds on Oxford BioDynamics' proven ability to develop predictive biomarkers for response in immuno-oncology, it said.
Under the terms, the unnamed partner will be granted access to Oxford BioDynamics' EpiSwitch technology for use in the development of predictive biomarkers.
Other details of the agreement and financial terms were not disclosed.
"We are delighted to have entered into this new agreement with a major US pharmaceutical company, built on the success of our prior predictive biomarker development and validation," said Oxford BioDynamics Chief Executive Christian Millar.
"We are pleased to be delivering robust biomarkers of high value to our clients, as part of our commercial presence in the US, and are excited to further demonstrate the value of EpiSwitch patient stratification, with all the potential it holds for drug development and personalized patient care," added Millar.
Oxford BioDynamics shares closed 14% higher on Friday in London at 118.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
